ImmuPharma (LON:IMM) Shares Down 8.3% – Time to Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s share price dropped 8.3% during trading on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). Approximately 7,864,863 shares traded hands during trading, a decline of 65% from the average daily volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).

ImmuPharma Price Performance

The stock has a market cap of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53. The business has a 50-day simple moving average of GBX 2.46 and a two-hundred day simple moving average of GBX 1.95.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.